Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by AnaptysBio, Inc. on June 17, 2025. The filing details the outcomes of five proposals submitted to security holders, including director elections, auditor ratification, executive compensation votes, and equity plan amendments.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following proposals were adopted or voted upon at the Annual Meeting:
- Director Elections: Three Class II directors were elected to three-year terms: Rita Jain, M.D., John Orwin, and J. Anthony Ware, M.D. Significant broker non-votes (approx. 1.59 million shares) were recorded for all three nominees.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with overwhelming support (27.2 million shares for vs. 17,021 against).
- Executive Compensation (Say-on-Pay): The non-binding advisory vote on executive compensation passed, though with notable opposition (17.8 million for vs. 6.6 million against).
- Equity Incentive Plan: Stockholders approved the amendment and restatement of the Company's 2017 Equity Incentive Plan (18.0 million for vs. 6.4 million against).
- Compensation Vote Frequency: Stockholders voted to hold future advisory votes on executive compensation annually (25.0 million votes for one year).
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary focus is the administrative record of the shareholder vote.
Investor Verification Checklist
- Verify the specific terms of the Amended and Restated 2017 Equity Incentive Plan (Exhibit 10.1) to understand changes to share reserves or vesting schedules.
- Review the 2025 Annual Proxy Statement for detailed biographies of the newly elected directors and the rationale behind the equity plan amendment.
- Monitor the opposition vote percentages on the Say-on-Pay and Equity Plan proposals, as they indicate potential shareholder sentiment regarding compensation and dilution.
- Confirm the broker non-vote implications for future director elections, as these votes were significant in this filing.